Dec 16, 2015

CardioCell Appoints Timothy Brown, J.D., as Vice President of Intellectual Property

SAN DIEGO — Dec. 16, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, today welcomes Timothy M. Brown, J.D., as its vice president of intellectual property. This news occurs when CardioCell is advancing at a rapid pace, having recently announced intention to proceed with Phase IIb clinical trials for its chronic heart failure study based on promising preliminary safety and efficacy data from its Phase IIa trial (NCT02123706). With licenses to practice law in California and before the United States Patent and Trade Office (USPTO), Brown will represent and protect the innovations CardioCell is developing with its stem cell therapies for cardiovascular indications.

“CardioCell is pleased to attract a candidate of Timothy Brown’s experience and caliber as its vice president of intellectual property,” says Dr. Sergey Sikora, CardioCell’s president and CEO. “His patent law and biotechnology expertise will be essential in helping CardioCell navigate this phase of accelerated advancement in stem cell therapies.”

Brown joins CardioCell after spending the past 10 years handling intellectual property and patent filings for biotech companies, including Fate Therapeutics Inc. and CardioCell’s parent company Stemedica Cell Technologies Inc. Before that he spent five years as a patent examiner in the USPTO. In his career he has prosecuted 13 issued patents, prepared 40 patent applications and has overseen the negotiation of several collaborations, including a joint research agreement with a Fortune 500 company. Ideally suited to handle biotech intellectual property, he brings both expertise in law and life sciences. He earned his J.D. cum laude from California Western School of Law; his MBA from California Polytechnic State University, San Luis Obispo; his M.S. in biotechnology from Johns Hopkins University; and his B.S. in cell and molecular biology from San Diego State University.

Brown will be protecting CardioCell’s cardiovascular therapies that uniquely feature itMSCs, which are exclusively licensed from CardioCell’s parent company Stemedica. Unlike all other MSCs – which are grown under normoxic conditions – Stemedica’s bone-marrow-derived, adult, allogeneic itMSCs are unique because they are grown under hypoxic conditions. In vitro experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to other MSCs, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.

About CardioCell LLC

Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. is a global biopharmaceutical company that manufactures multiple lines of allogeneic adult stem cells and stem cell factors. The company is licensed by the State of California’s Department of Public Health, Food and Drug Branch to manufacture cGMP, clinical-grade stem cells currently used in U.S.-based clinical trials for chronic heart failure, cutaneous photoaging, ischemic stroke and Alzheimer’s disease. Stemedica’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California and can be found online at www.stemedica.com.